Wnt induces FZD5/8 endocytosis and degradation and the involvement of RSPO-ZNRF3/RNF43 and DVL
- Key Laboratory of Molecular Biophysics of the Ministry of Education, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, China; Genetic Diseases Key Laboratory of Sichuan Province and the Department of Laboratory Medicine, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, China
- College of Life and Health Science, Northeastern University, China
- Center for Life Sciences, School of Life Sciences, Yunnan University, China
- The F. M. Kirby Neurobiology Center, Boston Children’s Hospital, Department of Neurology, Harvard Medical School, United States
- Research Unit for Blindness Prevention of the Chinese Academy of Medical Sciences (2019RU026), Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, China
Figures
Figure 1 with 1 supplement
Wnt induces FZD5/8 endocytosis and degradation.
(A) Wnt3a or Wnt5a specifically reduced the cell surface levels of V5-FZD5/8. HEK293A cells stably expressing each of the 10 V5-FZDs (FZD1 to 10) were treated with control, Wnt3a, or Wnt5a CM for 4 hours, and the cell surface levels of V5-FZDs were analyzed via flow cytometry using an anti-V5 antibody. (B) Wnt3a or Wnt5a specifically decreased the levels of mature forms of V5-FZD5/8. The whole cell lysates (WCLs) from the indicated cells treated as described in (A) were analyzed by immunoblotting with the indicated antibodies. (C) Bafilomycin A1 (BA1) restored Wnt3a or Wnt5a induced FZD5 degradation. (D) Schematic diagram of FZD5 constructs: full-length FZD5, FZD5 lacking the extracellular cysteine-rich domain (FZD5△CRD), and FZD5 lacking the intracellular C-terminus (FZD5△C). (E, F) HEK293A cells stably expressing the FZD5 truncation constructs shown in (D) were treated and analyzed as described in (A). (G) Schematic diagram of CRD-swapped chimeric FZDs. (H) HEK293A cells stably expressing the indicated chimeric FZD constructs shown in (F) were treated and analyzed as described in (A).
-
Figure 1—source data 1
Raw unedited blots for Figure 1.
- https://cdn.elifesciences.org/articles/103996/elife-103996-fig1-data1-v1.zip
-
Figure 1—source data 2
Uncropped and labeled blots for Figure 1.
- https://cdn.elifesciences.org/articles/103996/elife-103996-fig1-data2-v1.zip
Figure 1—figure supplement 1
Wnt induces FZD5/8 endocytosis and degradation.
(A) Wnt3a or Wnt5a specifically reduced the cell surface levels of V5-FZD5/8. Huh7 cells stably expressing each of the 10 V5-FZDs (FZD1 to 10) were treated with control, Wnt3a, or Wnt5a CM for 4 hr, and the cell surface levels of V5-FZDs were analyzed via flow cytometry using an anti-V5 antibody. (B) Wnt3a or Wnt5a specifically decreased the levels of mature forms of V5-FZD5. The whole cell lysates (WCLs) from the indicated U2OS cells treated as described in (A) were analyzed by immunoblotting with the indicated antibodies.
-
Figure 1—figure supplement 1—source data 1
Raw unedited blots for Figure 1—figure supplement 1.
- https://cdn.elifesciences.org/articles/103996/elife-103996-fig1-figsupp1-data1-v1.zip
-
Figure 1—figure supplement 1—source data 2
Uncropped and labeled blots for Figure 1—figure supplement 1.
- https://cdn.elifesciences.org/articles/103996/elife-103996-fig1-figsupp1-data2-v1.zip
Figure 2 with 3 supplements
Wnt induces ZNRF3/RNF43-dependent FZD5/8 endocytosis and degradation.
(A) Wnt3a or Wnt5a induced the degradation of endogenous FZD5. HEK293A cells with a V5 epitope tag knocked in at the C-terminus of endogenous FZD5 (FZD5KI) were treated with Wnt3a or Wnt5a CM for the indicated durations, and the WCLs were analyzed by immunoblotting with the indicated antibodies. Wild-type (WT) cells served as a negative control to confirm the specificity of the FZD5KI bands. The upper bands represent mature FZD5, whereas the lower bands represent immature FZD5. (B) Wnt3a or Wnt5a induced the degradation of endogenous FZD5 but not FZD7. FZD5KI or FZD7KI (generated as described for FZD5KI) HEK293A cells were treated with control, Wnt3a CM, or Wnt5a CM for 2 hr, and the WCLs were subjected to immunoblotting with the indicated antibodies. (C) The Porcupine inhibitor IWP-2 increased the level of the endogenous mature form of FZD5 but not FZD7. FZD5KI or FZD7KI cells were treated overnight with or without IWP-2 (2.5 μM), and the WCLs were subjected to immunoblotting with the indicated antibodies. (D, E) IWP-2 increased the cell surface levels of endogenous FZD5/8 but not FZD4. HEK293A WT cells were treated with or without IWP-2 and analyzed by flow cytometry to determine the FZD5/8 and FZD4 levels on the cell surface with anti-FZD5/8 (2919) or anti-FZD4 (5028) monoclonal antibodies. APC, allophycocyanin. (F, G) ZNRF3/RNF43 double knockout increased the cell surface levels of endogenous FZD5/8 but not FZD4. The cell surface levels of FZD5/8 and FZD4 in WT or ZRDKO cells were analyzed by flow cytometry. (H) Wnt-induced FZD5 degradation is dependent on endogenous ZNRF3 and RNF43. WT, FZD5KI, or ZRDKO-FZD5KI (ZNRF3/RNF43 double knockout cells with a V5 tag knocked in at the C-terminus of endogenous FZD5) cells were treated and analyzed as described in (B). (I) IWP-2 did not increase the endogenous FZD5 protein level in ZRDKO cells. (J) RSPO1 treatment increased the level of the mature form of endogenous FZD5 but not FZD7. FZD5KI and FZD7KI cells were treated with control or RSPO1 CM for 4 hr, and the WCLs were analyzed by immunoblotting with the indicated antibodies. (K) RSPO1 failed to increase the level of the mature form of FZD5 in ZRDKO cells. FZD5KI or ZRDKO-FZD5KI cells were treated and tested as described in (J). (L) RSPO1 treatment restored Wnt3a and Wnt5a induced membrane FZD5 degradation. HEK293A FZD5KI cells were incubated with EZ-link Sulfo-NHS-SS-Biotin to label membrane protein, then treated with control, Wnt3a, Wnt5a CM, or Wnt3a/Wnt5a with RSPO1 CM. Membrane proteins were bound by NeutrAvidin beads and eluted for immunoblotting. (M) IWP-2 and RSPO1 treatments similarly increased the FZD5/8 levels on the cell surface. WT cells were treated with IWP-2 overnight or RSPO1 for 4 hr, followed by flow cytometry analysis. (N, O) RSPO1 treatment did not increase the cell surface levels of FZD5/8 in ZRDKO cells or FZD4 in WT cells. HEK293A ZRDKO or WT cells were treated with control or RSPO1 CM for 4 hr and subjected to flow cytometry analysis with anti-FZD5/8 or anti-FZD4 monoclonal antibodies.
-
Figure 2—source data 1
Raw unedited blots for Figure 2.
- https://cdn.elifesciences.org/articles/103996/elife-103996-fig2-data1-v1.zip
-
Figure 2—source data 2
Uncropped and labeled blots for Figure 2.
- https://cdn.elifesciences.org/articles/103996/elife-103996-fig2-data2-v1.zip
Figure 2—figure supplement 1
IWP-2 increased the cell surface levels of endogenous FZD5/8 in several cell lines.
(A-C) IWP-2 increased the cell surface levels of endogenous FZD5/8 in Huh7(A), MCF7(B), and 769P(C) cells. The indicated cells were treated with or without IWP-2 and analyzed by flow cytometry to determine the FZD5/8 levels on the cell surface with anti-FZD5/8 (2919) monoclonal antibodies. APC, allophycocyanin.
Figure 2—figure supplement 2
Characterization of the antibodies used for flow cytometry in this study.
HEK293A WT cells or cells stably expressing each of the 10 V5-FZDs were analyzed by flow cytometry with the indicated antibodies.
Figure 2—figure supplement 3
Genetic lesions in ZRDKO cells.
Genomic DNA sequencing results showing mutations in ZNRF3 and RNF43 in ZRDKO clones. The reference nucleotide sequence (WT allele) is presented at the top. The sequences targeted by the sgRNA are highlighted in red, with cleavage sites indicated by red arrows.
Figure 3 with 1 supplement
DVL proteins participate in ligand-independent FZD protein endocytosis but are not required for Wnt-induced FZD5/8 endocytosis or degradation.
(A) Validation of HEK293A DVLTKO cells by immunoblotting analysis with the indicated anti-DVL antibodies. (B) Triple knockout of DVL1/2/3 increased FZD5/8 levels on the cell surface. WT and DVLTKO cells were analyzed by flow cytometry with an anti-FZD5/8 monoclonal antibody. (C, D) IWP-2 (C) or RSPO1 (D) treatment increased FZD5/8 levels on the cell surface of DVLTKO cells. DVLTKO cells were treated with IWP-2 overnight or RSPO1 for 4 hr, followed by flow cytometry analysis. (E) Wnt3a and Wnt5a treatment reduced the cell surface levels of V5-FZD5 in DVLTKO cells. HEK293A DVLTKO cells stably expressing V5-FZD5 were treated with control, Wnt3a CM, or Wnt5a CM for 4 hr and analyzed via flow cytometry with an anti-V5 antibody. (F) Wnt3a and Wnt5a treatment decreased the mature form of V5-FZD5 in DVLTKO cells. The cells in (E) were treated, and the WCLs were analyzed by immunoblotting with the indicated antibodies. (G, I) Triple knockout of DVL1/2/3 reduced ligand-independent FZD5 and FZD7 endocytosis, but had no effect on Wnt3a or Wnt5a induced FZD5 endocytosis. And DVLTKO cells re-expressing DVL2 rescued decreased FZD5 and FZD7 endocytosis caused by DVL1/2/3 triple knockout. HEK293A cells stably expressing V5-linker-FZD5 or V5-linker-FZD7 were first incubated with an anti-V5 antibody, and the cells were treated with control, Wnt3a, or Wnt5a CM for 1 hr and subjected to immunofluorescence analysis. The cells were treated with IWP-2 overnight prior to treatment with conditioned medium. Scale bars, 10 μm. (H, J) Quantification of the number of FZD5 (G) or FZD7 (I) puncta in WT, DVLTKO, and DVLTKO + DVL2 cells (mean ± SD, n=20 cells per group). ns, no significant difference; ***p<0.001; ****p<0.0001. (K) WCLs from WT, DVLTKO, and DVLTKO + DVL2 cells stably expressing V5-linker-FZD5 or V5-linker-FZD7 were analyzed by immunoblotting.
-
Figure 3—source data 1
Raw unedited blots for Figure 3.
- https://cdn.elifesciences.org/articles/103996/elife-103996-fig3-data1-v1.zip
-
Figure 3—source data 2
Uncropped and labeled blots for Figure 3.
- https://cdn.elifesciences.org/articles/103996/elife-103996-fig3-data2-v1.zip
Figure 3—figure supplement 1
Genetic lesions in DVLTKO cells.
Genomic DNA sequencing results showing mutations in DVL1, DVL2, and DVL3 in the DVLTKO clone. The reference nucleotide sequence (WT allele) is presented at the top. The sequences targeted by the sgRNA are highlighted in red, with cleavage sites indicated by red arrows.
Figure 4 with 1 supplement
ZNRF3/RNF43 is required for the degradation of internalized FZD5 but is dispensable for Wnt-induced FZD5 internalization.
(A) Wnt3a and Wnt5a induced V5-FZD5 endocytosis in ZRDKO cells. (B) Wnt3a and Wnt5a induced V5-FZD5 degradation in WT but not ZRDKO cells. (C) Wnt5a induced FZD5 internalization in both WT and ZRDKO cells, and internalized FZD5 gradually diminished in WT but not ZRDKO cells. WT or ZRDKO cells stably expressing V5-FZD5 were treated with control or Wnt5a CM for the indicated times and analyzed by immunostaining. The cells were treated with IWP-2 overnight prior to treatment with CM. Scale bars, 10 μm. (D) Cotreatment with RSPO1 prevented FZD5 degradation but had little effect on FZD5 internalization induced by Wnt5a. The cells were treated with IWP-2 overnight prior to treatment with CM. Scale bars, 10 μm. (E) Compared with those in WT cells, fewer V5-FZD5 puncta colocalized with the early endosomal marker EEA1 in ZRDKO cells. WT or ZRDKO cells stably expressing V5-FZD5 were treated with control or Wnt5a CM for 2 hr and then analyzed by immunostaining. The cells were treated with IWP-2 overnight prior to treatment with CM. Scale bars, 10 μm. (F) Quantification of the percentage of V5-FZD5 puncta colocalized with EEA1 in WT and ZRDKO cells (mean ± SD, n=20 cells per group). ****p<0.0001. (G) Compared with those in WT cells, fewer V5-FZD5 puncta colocalized with the lysosomal marker LAMP1 in ZRDKO cells. WT or ZRDKO cells stably expressing V5-FZD5 were treated with control or Wnt5a CM for 2 hr and then analyzed by immunostaining. The cells were treated with IWP-2 overnight prior to treatment with CM. Scale bars, 10 μm. (H) Quantification of the percentage of V5-FZD5 puncta colocalized with LAMP1 in WT and ZRDKO cells (mean ± SD, n=20 cells per group). ****p<0.0001.
-
Figure 4—source data 1
Raw unedited blots for Figure 4.
- https://cdn.elifesciences.org/articles/103996/elife-103996-fig4-data1-v1.zip
-
Figure 4—source data 2
Uncropped and labeled blots for Figure 4.
- https://cdn.elifesciences.org/articles/103996/elife-103996-fig4-data2-v1.zip
Figure 4—figure supplement 1
ZNRF3/RNF43 is required for the degradation of Wnt3a induced internalized FZD5.
(A) Wnt3a induced FZD5 internalization in both WT and ZRDKO cells, and internalized FZD5 gradually diminished in WT but not ZRDKO cells. WT or ZRDKO cells stably expressing V5-FZD5 were treated with control or Wnt3a CM for the indicated times and analyzed by immunostaining. The cells were treated with IWP-2 overnight prior to treatment with CM. Scale bars, 10 μm. (B) Cotreatment with RSPO1 prevented FZD5 degradation but had little effect on FZD5 internalization induced by Wnt3a. The cells were treated with IWP-2 overnight prior to treatment with CM. Scale bars, 10 μm.
Figure 5
ZNRF3/RNF43-mediated inhibition of Wnt signaling cannot be explained by simply regulating FZD levels on the cell surface.
(A) Flow cytometry analysis of FZD levels on the cell surface of WT HEK293A, ZRDKO (ZRDKO C1/2), and HEK293A cells stably expressing V5-FZD5/7 with an anti-pan-FZD monoclonal antibody. FZD levels on the cell surface were greater in ZRDKO cells than in WT cells but much lower than those in V5-FZD5/7-expressing cells. (B) Cytosolic β-catenin levels were significantly lower in V5-FZD5/7-expressing cells than in ZRDKO cells. (C) ZNRF3/RNF43 double knockout-induced DVL phosphorylation and cytosolic β-catenin accumulation depend on endogenous Wnt proteins. WT or ZRDKO cells were treated with or without IWP-2 and analyzed by immunoblotting. (D) Overexpressing V5-FZD5 or V5-FZD7 resulted in Wnt-independent DVL phosphorylation. V5-FZD5/7-expressing cells were treated with or without IWP-2, and the WCLs were analyzed by immunoblotting. (E) Expression of ZNRF3 or RNF43, but not RNF130 or RNF150, reversed the increase in cytosolic β-catenin levels in ZRDKO cells. (F) Overexpression of RNF43 or RNF150 reduced the levels of mature forms of V5-FZD5 or V5-FZD7. WCLs from HEK293A cells expressing V5-FZD5 or V5-FZD7 alone or together with RNF43-HA or RNF150-HA were analyzed by immunoblotting. (G) Overexpression of ZNRF3, RNF43, RNF130, or RNF150 in ZRDKO cells reduced FZD levels on the cell surface, as measured by flow cytometry with an anti-pan-FZD antibody. (H) Overexpression of ZNRF3, RNF43, RNF130, or RNF150 in ZRDKO cells reduced FZD5/8 levels on the cell surface. IWP-2 partially reversed the reduction in FZD5/8 levels induced by ZNRF3 or RNF43 but not by RNF130 or RNF150. The cells in (E) were treated with or without IWP-2 overnight and analyzed by flow cytometry with an anti-FZD5/8 monoclonal antibody.
-
Figure 5—source data 1
Raw unedited blots for Figure 5.
- https://cdn.elifesciences.org/articles/103996/elife-103996-fig5-data1-v1.zip
-
Figure 5—source data 2
Uncropped and labeled blots for Figure 5.
- https://cdn.elifesciences.org/articles/103996/elife-103996-fig5-data2-v1.zip
Figure 6 with 2 supplements
ZNRF3/RNF43 specifically inhibits FZD5/8-mediated Wnt signaling, whereas RSPO1 specifically potentiates FZD5/8-mediated Wnt signaling.
(A) Flow cytometry analysis of FZD5/8 levels on the cell surface in ZRDKO and ZRDKO-FZD5/8DKO cells with an anti-FZD5/8 antibody. (B) Depletion of FZD5/8 diminished the increase in cytosolic β-catenin levels in ZRDKO cells. Cytosolic fractions from the indicated cells were analyzed by immunoblotting. (C) Re-expression of V5-FZD5, but not V5-FZD7, restored cytosolic β-catenin levels in ZRDKO-FZD5/8DKO cells. (D) Overexpression of V5-FZD, but not V5-FZD7, further elevated cytosolic β-catenin levels in ZRDKO cells. (E, F) FZD5, but not FZD7, enhanced the inhibitory effect of RNF43 on Wnt3a signaling. HEK293A cells stably expressing RNF43-HA alone or with V5-FZD5 or V5-FZD7 were treated with increasing doses of Wnt3a for 2 hr, and the cytosolic fractions were analyzed by immunoblotting. (G) Flow cytometry analysis of cell surface FZD5/8 levels in WT or FZD5/8 DKO cells. (H, I) FZD5/8 double knockout abolished RSPO1-induced cytosolic β-catenin accumulation but had little effect on Wnt3a-induced increases in cytosolic β-catenin levels. The cells were treated with RSPO1 CM for 4 hr (H) or increasing doses of Wnt3a for 2 hr (I), and the cytosolic fractions were analyzed by immunoblotting. (J) WCLs from WT, FZD5/8 DKO and FZD5/8 DKO cells stably expressing V5-FZD5 or V5-FZD8 were analyzed by immunoblotting. (K) FZD5/8 double knockout abolished RSPO1-induced cytosolic β-catenin accumulation, which was restored by re-expressing V5-FZD5 or V5-FZD8.
-
Figure 6—source data 1
Raw unedited blots for Figure 6.
- https://cdn.elifesciences.org/articles/103996/elife-103996-fig6-data1-v1.zip
-
Figure 6—source data 2
Uncropped and labeled blots for Figure 6.
- https://cdn.elifesciences.org/articles/103996/elife-103996-fig6-data2-v1.zip
Figure 6—figure supplement 1
ZNRF3/RNF43 specifically regulates FZD5/8-mediated Wnt signaling.
(A) U2OS cells stably expressing RNF43-HA alone or together with V5-FZD5 or V5-FZD7 were analyzed by immunoblotting with the indicated antibodies to confirm protein expression. (B) Cells in (A) were treated with increasing doses of Wnt3a for 2 hr, and the cytosolic fractions were analyzed by immunoblotting. Notably, the expression of FZD5, but not FZD7, enhanced the inhibitory effect of RNF43 on Wnt3a signaling.
-
Figure 6—figure supplement 1—source data 1
Raw unedited blots for Figure 6—figure supplement 1.
- https://cdn.elifesciences.org/articles/103996/elife-103996-fig6-figsupp1-data1-v1.zip
-
Figure 6—figure supplement 1—source data 2
Uncropped and labeled blots for Figure 6—figure supplement 1.
- https://cdn.elifesciences.org/articles/103996/elife-103996-fig6-figsupp1-data2-v1.zip
Figure 6—figure supplement 2
Genetic lesions in ZRDKO-FZD5/8DKO and FZD5/8DKO cells.
(A, B) Genomic DNA sequencing results showing mutations in FZD5 and FZD8 in the ZRDKO-FZD5/8DKO (A) and FZD5/8DKO clones (B). The reference nucleotide sequence (WT allele) is presented at the top. The sequences targeted by the sgRNA are highlighted in red, and the cleavage sites are indicated by red arrows.
Figure 7 with 1 supplement
Wnt3a and Wnt5a induce the FZD5‒RNF43 interaction.
(A) Verification of protein expression and biotinylation efficiency in HEK293A ZRDKO cells stably expressing V5-FZD5-mTB or V5-FZD7-mTB alone or together with RNF43ΔRING-HA. The cells were treated with or without biotin (200 μM) and analyzed by immunoblotting with the indicated antibodies. (B) Wnt3a or Wnt5a induces interaction between FZD5 and RNF43△RING but not FZD7. The cells in (A) were treated with IWP-2, control, Wnt3a or Wnt5a conditional medium with or without biotin as indicated, and the WCLs were precipitated with NeutrAvidin agarose beads, followed by immunoblotting analysis. (C) Schematic model of Wnt-induced FZD5/8 endocytosis and degradation. In the presence of ZNRF3/RNF43, Wnt binds to FZD5/8 and forms a complex with ZNRF3/RNF43, leading to FZD5/8 endocytosis and subsequent lysosomal degradation. This process is not affected by the absence of DVL proteins. In the absence of ZNRF3/RNF43, Wnt still induces FZD5/8 endocytosis; however, endosomes containing FZD5/8 do not merge with lysosomes, resulting in the accumulation of mature FZD5/8 intracellularly.
-
Figure 7—source data 1
Raw unedited blots for Figure 7.
- https://cdn.elifesciences.org/articles/103996/elife-103996-fig7-data1-v1.zip
-
Figure 7—source data 2
Uncropped and labeled blots for Figure 7.
- https://cdn.elifesciences.org/articles/103996/elife-103996-fig7-data2-v1.zip
Figure 7—figure supplement 1
Wnt3a and Wnt5a induce the FZD5‒RNF43 interaction in DVLTKO cells.
(A) Verification of protein expression and biotinylation efficiency in HEK293A DVLTKO cells stably expressing V5-FZD5-mTB or V5-FZD7-mTB alone or together with RNF43ΔRING-HA. The cells were treated with or without biotin (200 μM) and analyzed by immunoblotting with the indicated antibodies. (B) Wnt3a or Wnt5a induces interaction between FZD5 and RNF43△RING but not FZD7 in DVLTKO cells. The cells in (A) were treated with control, Wnt3a, or Wnt5a conditional medium with or without biotin as indicated, and the WCLs were precipitated with NeutrAvidin agarose beads, followed by immunoblotting analysis.
-
Figure 7—figure supplement 1—source data 1
Raw unedited blots for Figure 7—figure supplement 1.
- https://cdn.elifesciences.org/articles/103996/elife-103996-fig7-figsupp1-data1-v1.zip
-
Figure 7—figure supplement 1—source data 2
Uncropped and labeled blots for Figure 7—figure supplement 1.
- https://cdn.elifesciences.org/articles/103996/elife-103996-fig7-figsupp1-data2-v1.zip
Author response image 1
High concentrations of Wnt3a or Wnt5a may interfere with the recognition of FZD5/8 by the anti-FZD5/8 antibody in flow cytometry assays.
(A) HEK293A cells were treated with control, Wnt3a or Wnt5a CM for 2 hours at 37°C in a humidified incubator and were analyzed via flow cytometry using the anti-FZD5/8 antibody. (B) HEK293A cells were incubated with control, Wnt3a or Wnt5a CM for 1 h at 4°C and analyzed by flow cytometry using the anti-FZD5/8 antibody.
Tables
Key resources table
| Reagent type (species) or resource | Designation | Source or reference | Identifiers | Additional information |
|---|---|---|---|---|
| Antibody | Rabbit monoclonal anti-HA | Cell Signaling Technology | Cat# 3724; RRID:AB_1549585 | WB(1:1000) |
| Antibody | Rabbit monoclonal anti-V5 | Cell Signaling Technology | Cat# 13202; RRID:AB_2687461 | WB(1:1000) IF(1:1000) FACS(1:500) |
| Antibody | Mouse monoclonal anti-V5 | Cell Signaling Technology | Cat# 80076; RRID:AB_2920661 | IF(1:1000) |
| Antibody | Rabbit polyclonal anti-Beta Catenin | Proteintech | Cat# 51067–2-AP; RRID:AB_2086128 | WB(1:10000) |
| Antibody | Rabbit polyclonal anti-DVL1 | Proteintech | Cat# 27384–1-AP; RRID:AB_2880859 | WB(1:1000) |
| Antibody | Mouse monoclonal anti-DVL2 | Proteintech | Cat# 67105–1-Ig; RRID:AB_2882409 | WB(1:2000) |
| Antibody | Rabbit polyclonal anti-DVL3 | Proteintech | Cat# 13444–1-AP; RRID:AB_2093451 | WB(1:2000) |
| Antibody | Rabbit monoclonal anti-ACTB | ABclonal | Cat# AC026; RRID:AB_2768234 | WB(1:10,000) |
| Antibody | Rabbit monoclonal anti-LAMP1 | Cell Signaling Technology | Cat# 9091; RRID:AB_2687579 | IF(1:500) |
| Antibody | Mouse monoclonal anti-EEA1 | Cell Signaling Technology | Cat# 48453, RRID:AB_2920538 | IF(1:500) |
| Antibody | Alexa Fluor 488 AffiniPure Donkey anti-Rabbit IgG (H+L) | Yeasen Biotech | Cat# 34206ES60; RRID:AB_2909605 | IF(1:400) |
| Antibody | Alexa Fluor 488 AffiniPure Donkey Anti-Mouse IgG(H+L) | Yeasen Biotech | Cat# 34106ES60; RRID:AB_2920874 | IF(1:400) |
| Antibody | Alexa Fluor 647 AffiniPure Donkey anti-Rabbit IgG (H+L) | Yeasen Biotech | Cat# 34213ES60 | IF(1:400) |
| Antibody | Alexa Fluor 647 AffiniPure Donkey Anti-Mouse IgG(H+L) | Yeasen Biotech | Cat# 34113ES60 | IF(1:400) |
| Antibody | Allophycocyanin-AffiniPure F(ab')2 Fragment Goat Anti-Rabbit IgG (H+L) | Jackson ImmunoResearch Labs | Cat# 111-136-144; RRID:AB_2337987 | FACS(1:200) |
| Antibody | Allophycocyanin-AffiniPure F(ab')2 Fragment Goat Anti-Mouse IgG (H+L) | Jackson ImmunoResearch Labs | Cat# 115-136-146; RRID:AB_2338651 | FACS(1:200) |
| Antibody | Peroxidase-AffiniPure Goat Anti-Rabbit IgG (H+L) | Jackson ImmunoResearch Labs | Cat# 111-035-003; RRID:AB_2313567 | WB(1:10,000) |
| Antibody | HRP-conjugated goat anti-mouse IgG (H+L) | Mabnus | Cat# GS80002 | WB(1:10,000) |
| Antibody | HRP-labeled Streptavidin | Beyotime | Cat# A0303 | WB(1:1000) |
| Antibody | Mouse monoclonal anti-pan-FZD (OMP-18R5) | Stagg and Dupont, 2014 | N/A | FACS(1:500) |
| Antibody | Mouse monoclonal anti- FZD5/8 (2919) | Pan et al., 2021 | N/A | FACS(1:500) |
| Antibody | Mouse monoclonal anti-FZD4 (5028) | Sachdev Sidhu et al., 2021 | N/A | FACS(1:500) |
| Chemical compound, drug | IWP-2 | Sigma–Aldrich | Cat# I0536 | N/A |
| Chemical compound, drug | D-Biotin | Sigma–Aldrich | Cat# B4639 | N/A |
| Chemical compound, drug | Bafilomycin A1 (BA1) | Selleck | Cat# S1413 | N/A |
| Cell line (Homo sapiens) | HEK293T | ATCC | Cat# CRL-11268 | N/A |
| Cell line (Homo sapiens) | HEK293A | Procell | Cat# CL-0003 | N/A |
| Cell line (Homo sapiens) | Huh7 | Procell | Cat# CL-0120 | N/A |
| Cell line (Homo sapiens) | MCF7 | Procell | Cat# CL-0149 | N/A |
| Cell line (Homo sapiens) | 769 P | Procell | Cat# CL-0009 | N/A |
| Cell line (Homo sapiens) | U2OS | ATCC | Cat# HTB-96 | N/A |
| Cell line (M. musculus) | L cell | ATCC | Cat# CRL-2648 | N/A |
| Cell line (M. musculus) | L-Wnt3a cell | ATCC | Cat# CRL-2647 | N/A |
| Cell line (M. musculus) | L-Wnt5a cell | ATCC | Cat# CRL-2814 | N/A |
Additional files
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Wnt induces FZD5/8 endocytosis and degradation and the involvement of RSPO-ZNRF3/RNF43 and DVL
eLife 14:RP103996.
https://doi.org/10.7554/eLife.103996.3
